Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical steroids added to systemic therapy for skin involvement in idiopathic granulomatous mastitis
IRCT20230822059222N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluocinolone, mometasone, methotrexate, corticosteroids, ciprofloxacin and 1 more in Granulomatous lobular mastitis (GLM) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Disappearance of inflammatory signs, Closure of fistula orifices and 1 more. Started Oct 2023; status: completed.
02
Drugs
fluocinolonemometasonemethotrexatecorticosteroidsciprofloxacin
03
Conditions
Granulomatous lobular mastitis (GLM)
Beyond the preview
Go deeper on IRCT20230822059222N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230822059222N1.